Hengrui Pharma (HKG: 01276) has announced that its major product, Iohexol Injection, has been newly included in the National Essential Medicines List (2026 Edition).
This inclusion follows a joint notification issued by the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration. The updated list is scheduled to take effect from September 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments